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Abstract
Background: AIDS continues to spread at an estimated 2.6 new million infections per year, making the prevention
of HIV transmission a critical public health issue. The dramatic growth in global resources for AIDS has produced a
steady scale-up in treatment and care that has not been equally matched by preventive services. This paper is a
detailed analysis of how countries are choosing to spend these more limited prevention funds.
Methods: We analyzed prevention spending in 69 low- and middle-income countries with a variety of epidemic
types, using data from national domestic spending reports. Spending information was from public and
international sources and was analyzed based on the National AIDS Spending Assessment (NASA) methods and
classifications.
Results: Overall, prevention received 21% of HIV resources compared to 53% of funding allocated to treatment
and care. Prevention relies primarily on international donors, who accounted for 65% of all prevention resources
and 93% of funding in low-income countries. For the subset of 53 countries that provided detailed spending
information, we found that 60% of prevention resources were spent in five areas: communication for social and
behavioral change (16%), voluntary counselling and testing (14%), prevention of mother-to-child transmission
(13%), blood safety (10%) and condom programs (7%). Only 7% of funding was spent on most-at-risk populations
and less than 1% on male circumcision. Spending patterns did not consistently reflect current evidence and the
HIV specific transmission context of each country.
Conclusions: Despite recognition of its importance, countries are not allocating resources in ways that are likely to
achieve the greatest impact on prevention across all epidemic types. Within prevention spending itself, a greater
share of resources need to be matched with interventions that approximate the specific needs and drivers of each
country’s epidemic.
Background
In the third decade of the HIV epidemic, people are
starting to adopt safer sexual behaviors, reflecting the
impact of HIV prevention and awareness efforts [1].
There is evidence linking prevention strategies to reduc-
tion of incidence through behavioral change programs
[2]. Also, there are reports of prevention program effec-
tiveness and published estimates of the effectiveness of
HIV prevention interventions in changing sexual beha-
viors [3,4]. However, some studies have shown that
countries often do not allocate resources in ways that
are likely to achieve the greatest impact; countries with
similar epidemic types and prevalence rates distribute
resources in radically different ways [5-7].
The United Nations Political Declaration on AIDS
called to expand prevention coverage by diversifying
approaches and intensify efforts to end new HIV infec-
tions and reaffirm that prevention of HIV must be the
cornerstone of national, regional and international
responses to the HIV epidemic [8]. Governments also
committed to re-double HIV prevention efforts by tak-
ing all measures to implement comprehensive, evidence-
based prevention approaches, taking into account local
circumstances, ethics and cultural values [8]. Even with
* Correspondence: Carlos_Avila@abtassoc.com
3Abt Associates, 4550 Montgomery Ave, Suite 800 North, Bethesda, MD
20814, USA
Full list of author information is available at the end of the article
Amico et al. BMC Public Health 2012, 12:221
http://www.biomedcentral.com/1471-2458/12/221
© 2012 Amico et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.gains in access to treatment, the number of people
newly infected continues to outpace those that are put
on treatment [9,10]. Prevention remains the paramount
challenge of the HIV epidemic and the modes of pre-
vention are evolving with the results of the HPT 052
study [11,12]. Even with gains in access to treatment
and a global decline in the number of new infections,
there were an estimated 2.6 million people newly
infected with HIV in 2010 [1].
As the AIDS epidemic continues to evolve, revealing
geographic variations between and within regions, coun-
tries are increasingly working to formulate responses
specific to their particular contexts [13]. With the conti-
nuing scale-up of the national and international AIDS
response, it is increasingly important to accurately track
the origin of funds and how they are spent at the
national level. This includes looking at whether coun-
tries are obtaining the maximum benefit and achieving
expected outcomes from their AIDS resources [14]. The
mapping of resource flows can help decision-makers
monitor the effectiveness of their national programs and
improve resource mobilization in underfunded areas. At
the global level, this allows the international community
to evaluate the status of its response and its financial
accountability.
Methods
An analysis of reported HIV prevention expenditures
from 69 low- and middle- income countries in 2008 was
conducted, taking into account epidemic types, preven-
tion spending categories and country income levels. A
subset of 53 countries contained detailed information by
spending category. All expenditures, by programmatic
activity and HIV services, were cross-tabulated by
source of financing and stratified by income level.
Spending information from public and international
sources was analyzed based on the National AIDS
Spending Assessment (NASA) methods and classifica-
tions [15]. Total prevention spending was collected
using United Nations General Assembly Special Session
on HIV/AIDS (UNGASS) Indicator No. 1 reports [14].
This indicator reports on domestic and international
spending on AIDS by country, broken down into spend-
ing subcategories.
NASA is a tool developed by UNAIDS to measure all
the resources included in a country’sn a t i o n a lH I V
response and is based on the national health accounts
framework [16,17]. In addition to reporting on UNGASS
progress, the NASA methodology has been used to sup-
port countries in planning and monitoring their HIV
activities. NASA applies standard accounting methods
to reconstruct all transactions in a given country, ‘fol-
lowing the money’ from the funding sources to agents
and providers, and eventually to beneficiary populations.
These data are collected from every institution and
organization that intervenes financially in the national
response to HIV. And they are collected by the coun-
try’s NASA taskforce and entered into a Resource
Tracking System (RTS).
Countries were classified by national income level.
Economies were divided according to their Gross
National Income (GNI) per capita for the data collection
year used, calculated using the World Bank Atlas Meth-
ods and grouped into four categories: low-income (US$
935 or less); lower middle-income (US$ 936 - $3,705);
upper middle-income (US$ 3,706 - $11,455); and high
income (US$ 11,456 or more) [18]. All prices were con-
verted into constant 2008 dollars.
Finally, countries were grouped by type of HIV epi-
demic using UNAIDS and WHO classification criteria
[19]. This classification identifies three epidemic types-
low level, concentrated and generalized-based on the
current state of the epidemic and prevalence levels in
each country. Low-level epidemics are defined as having
prevalence below 1% in the general population. Concen-
trated epidemics are not yet generalized, but have
expanded to greater than five percent among any sub-
population group and are largely confined to most-at-
risk populations-commercial sex workers (CSW), men
who have sex with men (MSM) and injecting drug users
(IDU).
South Africa is notably absent, due to the fact that
they did not report their HIV spending in 2008.
Results
The 69 low- and middle-income countries with available
data spent a total of US$ 5.1 billion on the AIDS
response in 2008. Out of the 69 countries, there are 32
low-income countries, 26 lower middle-income coun-
tries and 11 upper middle-income countries. Prevention
amounted to US$ 1.1 (+/- 22 million) billion of this
total (21%); however, the majority of spending was
focused on treatment and care (53%). Table 1(Reported
total and per capita prevention spending, proportion of
international funding and overall HIV funding allocated
to prevention by epidemic type for 69 countries, in order
of per capita spending, 2008 (USD)) shows the absolute
and per capita amounts spent on prevention by epi-
demic type, the level of financing coming from interna-
tional sources, the proportion of overall HIV resources
that were allocated to prevention and countries’ ranking
with respect to per capita spending.
The study includes 15 countries with low-level epi-
demics, 28 with concentrated epidemics and 26 with
generalized epidemics. Once adjusted by the size of
their populations, countries with generalized epidemics
showed higher average per capita spending on preven-
tion-US$ 1.82 (Range .28-15.37) compared to US$ 0.68
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Page 2 of 10Table 1 Reported total and per capita prevention spending, proportion of international funding and overall HIV
funding allocated to prevention by epidemic type for 69 countries, in order of per capita spending, 2008 (USD)
Country % HIV spending
allocated to
prevention
Total prevention
spending (USD
thousands)
% of total prevention spending
funded by international donors
Per capita
prevention
spending
Ranking by per capita
prevention spending
Low-level epidemics
Kyrgyzstan 63 5,547 88 1.01 17
Georgia 40 3,218 77 0.75 24
Cuba 12 5,543 25 0.48 35
Tajikistan 47 2,930 77 0.42 42
Azerbaijan 70 3,512 27 0.39 45
Iran (Islamic
Republic of)
57 20,402 9 0.27 51
Lao People’s
Democratic
Republic
31 1,571 100 0.25 55
Bolivia 40 2,178 60 0.22 56
Bangladesh 69 25,566 100 0.16 61
Morocco 37 4,685 71 0.14 62
Pakistan 68 9,709 24 0.06 65
Sri Lanka 66 1,030 100 0.05 66
Philippines 53 3,462 74 0.04 67
Egypt 35 2,601 50 0.03 68
Algeria 11 432 41 0.01 69
Concentrated epidemics
Republic of
Moldova
70 8,966 59 2.28 6
Honduras 59 14,420 56 1.86 9
Costa Rica 33 6,480 9 1.39 11
El Salvador 21 8,338 25 1.35 12
Cambodia 38 19,929 79 1.31 13
Belarus 66 12,365 14 1.25 14
Chile 23 20,321 2 1.19 15
Mali 30 11,987 91 0.98 18
Argentina 14 35,216 12 0.88 22
Thailand 22 45,287 21 0.71 25
Dominican
Republic
23 5,450 73 0.52 33
Ukraine 23 22,808 63 0.48 36
Peru 34 14,135 73 0.47 37
Mexico 19 50,606 1 0.45 39
Colombia 20 20,788 0 0.45 40
Viet Nam 36 39,344 89 0.44 41
Malaysia 45 11,000 0 0.39 44
Armenia 42 1,100 77 0.36 47
Gambia 11 563 100 0.34 49
Myanmar 47 15,546 94 0.27 52
Panama 7 922 77 0.26 53
Madagascar 42 5,003 75 0.26 54
Brazil 7 41,759 3 0.21 57
Venezuela 8 5,662 1 0.20 58
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Page 3 of 10(Range .10-2.28) in concentrated epidemics and US$
0.29 (Range .01-1.01) in low-level epidemics. The great-
est share of HIV resources going to prevention was in
low-level epidemics, where 45% of funds went to pre-
vention, compared to 20% in concentrated epidemics
and 21% for generalized epidemics. Figures 1, 2 and 3
provide a breakdown of HIV spending by epidemic type
and income level for all countries. Prevention spending
patterns vary greatly, even among similar epidemic pro-
files and income levels.
Currently, prevention relies heavily on international
donors. On average 38% of total financing for preven-
tion came from domestic-public sources, in contrast to
the 63% of total treatment expenditures that were
funded domestically. International funding for preven-
tion was highest in low-income countries, where it
reached a median value of 95% (Range 24-100%), com-
pared to 59% (Range 0-100%) in lower-middle income
countries and 8% (Range 0-100%) in upper-middle
income ones. In 46 countries, international sources were
responsible for over 60% of prevention resources, with
contributions of greater than 80% in 31 of those coun-
tries. The majority of these are low-income countries,
although this group also included Equatorial Guinea.
Many of the countries benefitting from international
assistance were from sub-Saharan Africa, which
Table 1 Reported total and per capita prevention spending, proportion of international funding and overall HIV fund-
ing allocated to prevention by epidemic type for 69 countries, in order of per capita spending, 2008 (USD) (Continued)
Niger 23 2,822 96 0.20 59
Paraguay 13 1,164 51 0.18 60
Somalia 18 1,088 100 0.12 63
Indonesia 50 24,703 61 0.10 64
Generalized epidemics
Botswana 9 29,766 66 15.37 1
Lesotho 12 9,869 67 4.84 2
Kenya 24 158,619 97 4.14 3
Rwanda 26 29,308 98 3.16 4
Gabon 38 4,542 8 3.11 5
Uganda 22 64,185 100 1.97 7
Mozambique 27 38,543 97 1.86 8
Malawi 19 20,598 98 1.42 10
Congo 35 4,118 100 1.12 16
Cote d’Ivoire 31 19,417 99 0.94 19
Togo 38 5,887 97 0.89 20
Burkina Faso 27 12,956 71 0.88 21
Guinea-Bissau 34 1,238 96 0.78 23
Eritrea 25 3,574 93 0.71 26
Central African
Republic
15 3,031 92 0.70 27
Angola 38 12,215 16 0.68 28
Benin 28 5,745 81 0.65 29
Senegal 28 7,148 87 0.60 30
Cameroon 29 11,435 82 0.59 31
Burundi 22 5,736 81 0.54 32
Chad 38 5,323 100 0.49 34
Equatorial Guinea 12 329 100 0.47 38
Guinea 31 4,087 100 0.40 43
Nigeria 15 57,949 89 0.38 46
Ghana 22 8,307 83 0.35 48
Democratic
Republic of the
Congo
21 18,115 97 0.28 50
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Page 4 of 10registered both the highest levels of per capita spend-
ing on prevention and the greatest proportion of
resources coming from international donors. Sub-
Saharan Africa received 90% of its prevention
resources from international donors, compared to 62%
in South and South East Asia, 54% in Eastern Europe
and Central Asia, 27% in the Middle East and North
Africa, and 15% in Latin America and the Caribbean.
Per capita, sub-Saharan African countries spent US$
1.01 on prevention, the highest among any other
region. Eastern Europe and Central Asia was the sec-
ond highest spender at US$ 0.67 per capita, followed
by Latin America and the Caribbean at US$ 0.43,
S o u t ha n dS o u t hE a s tA s i aa tU S $0 . 2 1a n dt h eM i d d l e
East and North Africa at US$ 0.12.
In absolute terms, Kenya (US$ 158. 6 million), Uganda
(US$ 64.2 million), Nigeria (US$ 57.9 million), Mexico
(US$ 50.6 million) and Thailand (US$ 45.3 million) are
the biggest prevention spenders. Botswana (US$ 15.37),
which has invested heavily in its AIDS programs in
recent years, has the highest per capita spending, fol-
lowed by Lesotho (US$ 4.84), Kenya (US$ 4.14), Rwanda
(US$ 3.16) and Gabon (US$ 3.11). Figure 4 is a
representation of the 25 countries that spent the most
on prevention and it shows both domestic and public
sources of finance. Among the top 25 spenders, 12
relied on international sources for over 75% of their
expenditures.
Table 2 (Total and proportional spending per preven-
tion category in 53 countries, by epidemic type, 2008
(USD thousands)) presents expenditure by type of epi-
demic in relation to 23 prevention categories for the
subset of 53 countries that provided detailed reports.
Communication for social and behavioral change (16%),
voluntary counselling and testing (14%) and prevention
of mother-to-child transmission (13%) received the lar-
gest share of funds. These were followed by blood safety
(10%) and prevention and treatment of STIs (6%). Nota-
bly, male circumcision and post-exposure prophylaxis
both received less than 1% of overall prevention funding.
Condom-related categories including, social marketing,
public and commercial sector male/female condom pro-
vision, accounted for 7% of funding.
Programs for the most-at-risk-populations (MARPS)
each received 3% or less of overall funding, although pro-
portional spending was higher in low-level epidemics.
Figure 1 Proportional distribution of AIDS spending in 15 low-level epidemics, by income level 2008 (USD).
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Page 5 of 10Overall, low-level epidemics spent 25% of their preven-
tion budget on higher risk groups, compared to 12% in
concentrated epidemics and just over 1% in generalized
epidemics. This was due mainly to higher investments in
harm reduction programs, which received 15% of preven-
tion funds in low-level epidemics, compared to 5% of
total resources in concentrated epidemics and less than
1% in generalized epidemics. Programs for MSM were
allocated 4% or less of resources in each epidemic type,
while initiatives targeting CSWs received 6% or less.
Discussion
T h ec o u n t r i e si nt h i ss t u d ys p e n tj u s to v e raf i f t ho fa l l
resources for their AIDS response on prevention, pro-
viding a detailed picture of programmatic allocations of
just over US$ 1 billion. While this analysis focused on
prevention, these investments took place within the lar-
ger context of concurrent expenditures on treatment
and care, orphans and vulnerable children, and program
support and research, which brought total AIDS spend-
ing in 2008 to US$ 5.1 billion in the countries studied.
Many of the prevention categories have low proportions
of spending, but this does not necessarily mean that the
spending is insufficient. This depends on the size of the
target population and the amount that is spent. The
recent Investment Framework proposes focused pro-
grams for high risk populations, elimination of HIV
infections in children, reduction of risk through beha-
viour change, enhanced condom programs, treatment
for people living with HIV and voluntary male circumci-
sion in countries with high prevalence and low circum-
cision rates [20].
International funding is particularly prominent in pre-
vention activities focused on MARPS, where it is the
main source of overall funding, but it is likely that
broader issues related to stigma, political will and
human rights remain significant factors influencing
domestic resource allocations. At least 42 countries in
the study have laws criminalizing activities related to
one or more MARPS [21]. Decreased donor contribu-
tions will result in reduced funding for these groups and
domestic resources do not often make up the gap. Sus-
taining long-term preventive services in these popula-
tions could present a serious challenge, particularly in
low-income countries.
Of the 26 countries with generalized epidemics in the
study, 25 are located in sub-Saharan Africa, a region
which accounts for an estimated two-thirds of the global
Figure 2 Proportional distribution of AIDS spending in 28 concentrated epidemics, by income level 2008 (USD).
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Page 6 of 10HIV epidemic [22]. In these countries, it is essential to
address sexual prevention, which have been reported as
a key factor in the region’s high levels of HIV transmis-
sion [9]. This requires simultaneous implementation of
a variety of risk-reduction strategies. A key approach
typically relies on messaging targeting a particular sub-
population. In the 22 countries with generalized epi-
demics that provided a detailed breakdown of their
spending, mass media campaigns, community mobiliza-
tion and workplace prevention programs together
accounted for 27% of prevention spending. VCT
received 17%, while 20% was invested in PMTCT and
5% was put towards ensuring a safe blood supply. Com-
munication for behavioral change was the top preven-
tion spending category in generalized epidemics. Uganda
has experienced success through its 1987 “Zero Grazing”
campaign and appears to have reduced the percentage
of men having multiple partnerships [23].
Currently, there is wide interest in using antiretroviral
therapy as a means to prevent HIV transmission [24,25].
Evidence from PMTCT programs and follow-up studies
of discordant couples has demonstrated a significant
reduction in HIV transmission through ART [26]. Preli-
minary results from the HPTN 052 study show that
ART is 96% effective in preventing transmission to an
uninfected sexual partner in discordant couples where
the index case has CD4 counts between 350 and 550
[11]. It is therefore plausible that early antiretroviral
therapy and wide coverage could reduce community
viral loads and significantly reduce the number of new
cases of HIV [27,28]. HIV testing can act as an entry
point to both effective prevention and treatment, and
bridge the gap between these two approaches.
Increasing consistent use of condoms requires strate-
gies that go beyond supplying condoms to increase
demand and motivation for their use. Roughly, four per-
cent of spending in generalized epidemics was allocated
to the provision of condoms, while 3% of resources
were used for condom social marketing activities. A few
countries in the region did direct a large proportion of
their prevention resources to condom-programs.
In generalized epidemics in sub-Saharan Africa male
circumcision accounts for a small proportion of overall
spending, with only four countries reporting expendi-
tures in this area. Male circumcision has been shown to
be highly cost effective [29,30]. A randomized control
trial found that male circumcision has the potential to
reduce the risk of HIV in men by 60% [29]. The lack of
Figure 3 Proportional distribution of AIDS spending in 26 generalized epidemics, by income level 2008 (USD).
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Page 7 of 10spending in this area may be understandable, given that
wide advocacy for this option really began in 2008. In
June 2009, Population Services International received a
five-year, US $50 million grant from the Bill and
Melinda Gates Foundation to provide voluntary male
circumcision services to 650,000 men in Swaziland and
Zambia, while Zimbabwe has expanded a pilot program
and is now aiming to circumcise 80% of its male popu-
lation by the end of 2025 [30,31]. There will likely be
priority shifts and new trends in the future.
This study has several limitations; there is a lack of
data to compare observed HIV spending levels with
spending targets or populations at risk in the country.
T h ed a t at h a td oe x i s ta r eh i g h l yu n r e l i a b l ea n dt h e
authors determined that it was more instructive to pre-
sent a global perspective of prevention than to compare
spending to target population size. Also, expenditures
are estimated using different sources of information and
some countries lack comprehensive and regular expen-
diture records and accounting information systems. This
analysis does not include out-of-pocket expenditures;
although out-of-pocket spending has been found to vary
from 23 to 68% of total health expenditures, the
proportion that households divert to the purchase of
condoms, HIV testing, clean syringes or other preventive
interventions is unknown [32].
Conclusions
Substantial changes are needed to achieve a more tar-
geted and strategic approach to investment in the
response to the HIV/AIDS epidemic that will yield long-
term dividends. Until now, advocacy for resources has
been done on the basis of a commodity approach that
encouraged scaling up of numerous strategies in parallel,
irrespective of their relative effects [20]. The United
Nations Political Declaration on AIDS commits to
ensure that financial resources for prevention are tar-
geted to evidence-based prevention measures that reflect
the specific nature of each country’s epidemic by focus-
ing on geographic locations, social networks and popula-
tions vulnerable to HIV infection [8]. It is important
that prevention and treatment be viewed not as compet-
ing interests, but as complementary activities that
together provide the basis for combined prevention
approaches that address each country’sc o n t e x t .T h i s
overview of prevention spending may be a catalyst for
Figure 4 Annual prevention spending from public and international sources, 25 top spending countries, 2008 (USD).
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Page 8 of 10further research into a more strategic use of prevention
investments.
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